Senzime Q4 2025: Accelerated Growth and Continued Clear Path to Profitability

Rhea-AI Summary

Senzime (OTCQX:SNZZF) reported strong 2025 growth with net sales +78% to MSEK 104.0 and currency-adjusted sales of MSEK 111.2. Q4 net sales rose 102% to MSEK 28.3 (currency-adjusted MSEK 31.5).

Gross margin before depreciation fell to 52.6% for 2025 (adjusted 62.9% after a MSEK 10.7 inventory write-down). Operating profit before depreciation improved to MSEK -88.4 (adjusted). Cash was MSEK 74.0 at year-end. Company aims for profitability and positive cash flow in 2026.

Positive

• Net sales +78% to MSEK 104.0 in 2025
• Currency-adjusted sales +90% to MSEK 111.2
• Q4 net sales +102% to MSEK 28.3
• Adjusted gross margin 62.9% after MSEK 10.7 write-down
• Secured major hospital orders and regulatory approval in Japan

Negative

• Profit after financial items MSEK -43.1 for 2025
• Earnings per share SEK -0.27 in 2025
• Cash reduced to MSEK 74.0 from MSEK 100.9 year‑earlier
• Gross margin compressed by US tariffs and currency effects

UPPSALA, SE / ACCESS Newswire / February 18, 2026 / Senzime AB's (publ.) (STO:SEZI)(OTCQX:SNZZF) year-end report for January - December 2025 is now available on the company's website www.senzime.com.

Financial summary October-December 2025

• Net sales increased by 102 percent to MSEK 28.3 (14.0)

• Currency-adjusted net sales amounted to MSEK 31.5, an increase of 125 percent

• Gross margin before depreciation amounted to 25.1 percent (67.4) affected by currency effects, US tariffs and inventory write-down of MSEK 10.7

• Gross margin adjusted for inventory write-down amounted to 62.7 percent

• Operating profit before depreciation adjusted for inventory write-down amounted to MSEK -24.6 (-25.9)

• Profit after financial items amounted to MSEK -43.1 (-27.8)

• Earnings per share amounted to SEK -0.27 (-0.20)

• Cash and cash equivalents as of 31 December 2025 amounted to MSEK 74.0 (100.9)

Financial summary January-December 2025

• Net sales increased by 78 percent to MSEK 104.0

• Currency-adjusted net sales increased by 90 percent to MSEK 111.2

• System sales increased by 98 percent to MSEK 38.2 and sales of disposable sensors increased by 68 percent to MSEK 65.8

• Gross margin before depreciation amounted to 52.6 percent (64.4)

• Gross margin before depreciation adjusted for inventory write-down of MSEK 10.7 amounted to 62.9 percent.

• Operating profit before depreciation adjusted for inventory write-down improved by 16 percent to MSEK -88.4 (-105.5)

Strategic events during and after the end of the fourth quarter

• Senzime welcomes the first ever guidelines for EMG-based neuromuscular monitoring of children

• • Launch of EMGINE™ Sirius, next generation software for the TetraGraph system

• • Senzime secures major orders for TetraGraph systems from leading NHS hospital systems in the UK

• • Next-generation TetraGraph system receives regulatory PMDA approval in Japan

• • Senzime secures major agreements with leading Ivy League hospitals in the US

• Senzime secures credit facility totaling SEK 50 million on market terms

Philip Siberg, CEO, comments:

2025 was the year we increased the growth rate and exceeded SEK 100 million in sales. We won a number of major strategic deals, consolidated our leading market position and now have a clearly defined path to profitability ahead of us. Growth in 2025 amounted to 90 percent in constant currencies, corresponding to sales of SEK 111 million. In actual currencies, growth amounted to 78 percent. Behind the increase are even more hospital contracts won and increased utilization rates among existing customers. The fourth quarter ended the year strong with 125 percent growth in constant currencies and 102 percent in actual currencies.

We achieved our communicated target for sales growth in constant currencies and kept costs according to plan. The strengthened krona negatively affected sales figures in 2025 by approximately SEK 7.3 million. This hit the gross margin, which was also negatively affected by new US tariffs. Regardless of these items, the underlying gross margin improved through lower manufacturing costs and an increasing share of sales of disposable sensors.

In 2026, we aim for profitability by the end of the year. Given the large fluctuations in the dollar exchange rate, we clarify the goals for 2026 to maintain strong sales growth in line with recent years and achieve positive cash-flow within the fourth quarter. We do this through the expected strengthened gross margin, stable operating expenses and sales growth with an increasing share of recurring revenues.

Presentation of Senzime's Year-End Report January - December 2025
Senzime invites you to a webcast presentation of the 2025 Year-End Report on February 18, 2026 at 09:00. The presentation will be held by CEO Philip Siberg and will be in English. The webcast and presentation can be viewed on Senzime's website via the link www.senzime.com/sv/investerare.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.

Attachments

Senzime Year End Report Q4 2025

SOURCE: Senzime

View the original press release on ACCESS Newswire

FAQ

What were Senzime's (SNZZF) full-year 2025 net sales and growth rates?

Full-year 2025 net sales were MSEK 104.0, up 78% year-over-year. According to the company, currency-adjusted net sales rose 90% to MSEK 111.2, reflecting stronger underlying demand and higher recurring sensor sales.

How did Senzime's (SNZZF) gross margin and inventory write-down affect 2025 results?

Reported gross margin before depreciation was 52.6%, adjusted to 62.9% after a MSEK 10.7 inventory write-down. According to the company, currency effects and US tariffs compressed margins despite lower manufacturing costs.

What cash and profitability targets did Senzime (SNZZF) announce for 2026?

Senzime aims for profitability and positive cash-flow by the end of 2026, targeting positive cash-flow within Q4. According to the company, this relies on improved gross margin, stable operating expenses, and continued sales growth.

How did Senzime (SNZZF) perform in the fourth quarter of 2025?

In Q4 2025 net sales increased by 102% to MSEK 28.3 (currency-adjusted MSEK 31.5, +125%). According to the company, Q4 strength was driven by major hospital orders and higher utilization from existing customers.

What strategic milestones did Senzime (SNZZF) report in Q4 2025 and after year-end?

Senzime secured major orders from NHS and Ivy League hospitals, launched EMGINE Sirius, and gained PMDA approval in Japan. According to the company, these milestones strengthen commercialization and global market access for TetraGraph.